822-823 / 1578
Tumors abutting or invading chest wall
ASTRO evidence-based guideline, Videtic GMM, PRO 2017
SBRT is an appropriate option for treatment and should be offered for
T1-2
tumors
that abut the chest wall. Grades 1-2 chest wall toxicity is a common
occurrence post SBRT that usually resolves with conservative management.
•
Recommendation strength:
Strong
•
Quality of evidence:
High
•
Consensus:
94%
SBRT may be utilized in patients with
cT3 disease
due to chest wall invasion
without clear evidence of reduced efficacy or increased toxicity compared to
tumors abutting the chest wall.
•
Recommendation strength:
Conditional
•
Quality of evidence:
Low
•
Consensus:
88%